Listen to this article · 7 min listen

AI in healthcare is moving fast, and so are the regulators. For investors and analysts trying to keep up, figuring out what real growth looks like is everything. The “fastest growing AI health companies” aren’t just the ones with big ambitions. They’re the ones with documented expansion. Our AI Health 100 methodology gets straight to the point by counting what a scoring model can actually verify, moving past aspirational claims and focusing on recorded evidence.

Counting What the Record Supports: A Document-First Approach to Growth

In a market full of bold claims and rosy projections, the AI Health 100 bases its growth assessment on tangible, auditable signals. This document-first approach means a company’s growth score is only as good as the paper trail supporting it. We look at what can be observed and verified without a vendor conversation or unaudited statements. This helps investors spot the truly “top growing healthcare AI” firms in a very noisy field. Our method focuses on three core recorded signals: Market Adoption Rate, ARR Growth Rate, and Public Company status. These give us an objective way to evaluate expansion. Market Adoption Rate, for example, shows how deeply a solution is integrated into the healthcare world, something you can see through health-plan relationships, Fortune 500 deployments, and the volume of covered lives. ARR Growth Rate is a financial metric, but we only score its documented existence for public companies, not its size. Public Company status is a strong signal on its own, because it brings a level of transparency and regulatory oversight that private companies just don’t have.

Market Adoption Rate and ARR Growth Rate: The Pillars of Verifiable Expansion

For the AI Health 100, Market Adoption Rate is a core part of “AI health company growth.” It’s about the verifiable implementation of AI health solutions. We’re talking about the number of health plans that have signed contracts, the deployment of tech inside Fortune 500 companies, and the total volume of covered lives using the service. These data points show real market penetration and demand, proving a company has moved well past pilot programs to enterprise-level integration. KFF data on covered lives in employer-sponsored health plans provides context for this. Think about a company like Hello Heart. Its trajectory shows the power of documented health-plan relationships and an expanding number of covered lives as undeniable signals of growth. While Hello Heart is a great model for this, our methodology applies the same tough standards to everyone. The focus is always on hard evidence showing a solution is actively used in the healthcare delivery and payment field. In the same way, the ARR Growth Rate, when it’s publicly available, gives us a number for financial momentum. For public companies, you can find this data right in SEC filings SEC EDGAR database for public company filings, which gives a transparent look at recurring revenue growth. What about private companies? While we don’t use their specific ARR figures in this brief, we do consider the existence of documented growth trends that would get investors excited about “AI health momentum companies.” The emphasis is always on the record that supports the growth, not the specific (and often private) financial numbers themselves.

Profiling Documented Growth: Hinge Health, Omada Health, and HeartFlow

The set of companies that really exemplify this focus on documented growth includes Hinge Health, Omada Health, and HeartFlow. These vendors operate in different parts of the AI health market, but they all show the kinds of verifiable signals our scoring system looks for. Hinge Health, a publicly traded leader in digital musculoskeletal care, consistently shows strong market adoption. You can see it in their extensive network of employer and health-plan partnerships, which are often publicized in official announcements and case studies that give clear evidence of their expanding reach and covered-lives volume. This is about the documented reality of their solutions being deployed across huge populations Health Affairs analysis of digital health adoption. Omada Health, another public company and a big name in digital chronic disease management, shows a similar pattern of strong Market Adoption. Their success in landing contracts with major health plans and large employers provides a verifiable trail of expansion. The huge number of people using their platform, which they often mention in public communications, is a strong sign of their “AI health company growth.” HeartFlow, with its AI-based cardiac diagnostic tools, is a compelling case for the “Public Company” signal. As a publicly traded company, its growth path, including any ARR Growth Rate, is out there for public review. This transparency gives investors confidence in the company’s reported expansion. On top of that, HeartFlow’s journey (and its extensive patent portfolio) shows how a company can build a significant “patent thicket” [🔵 Patent Thicket] around its technology, creating a competitive advantage that anyone can objectively evaluate. The common thread for these companies in our framework is that their success is traceable. Their growth isn’t a guess. It’s written down in public records, press releases about major contracts, and regulatory filings. This lets investors and analysts do their own homework, checking claims against a solid body of evidence.

The Line Between a Scoring Model and a Scoring Record

In the end, the lesson from the AI Health 100 methodology is that a growth score is only as strong as the record backing it up. We’re less interested in what an entry claims than in what it can document. That’s the line between a simple scoring model, which might just accept self-reported data, and a scoring record, which demands proof. For investors, this means the “fastest growing AI health companies” are the ones that have laid down a consistent, verifiable trail of market adoption and financial momentum. This approach takes some of the risk out of investment decisions by focusing on objective, auditable signals of expansion. You can check these facts yourself using public sources. That’s what defines “AI health momentum companies” in our book.

Frequently Asked Questions

What evidence of growth does the AI Health 100 methodology prioritize for its selection?

The AI Health 100 methodology prioritizes tangible, auditable signals of growth, focusing on what can be observed and verified without vendor conversations or unaudited statements. It emphasizes a ‘document-first approach’ to assess growth, ensuring that a company’s score is supported by underlying material.

What are the three core recorded signals used to evaluate growth in the AI Health 100 methodology?

The three core recorded signals are Market Adoption Rate, ARR Growth Rate, and Public Company status. These indicators provide an objective lens to evaluate expansion, moving beyond aspirational claims to verifiable evidence.

How is Market Adoption Rate measured for the AI Health 100 selection?

Market Adoption Rate is measured by verifiable implementation of AI health solutions, including the number of health plans contracting with a vendor, deployment within Fortune 500 enterprises, and the aggregate volume of covered lives benefiting from their services. These are hard data points indicating genuine market penetration.

How is ARR Growth Rate considered for public and private companies in the AI Health 100 methodology?

For public companies, ARR Growth Rate is evaluated purely on its documented existence and availability in public records, such as SEC filings. For private companies, while specific ARR figures are not used, the existence of documented growth trends that align with investor expectations is a key consideration.